From RuntimeWire · RuntimeWire · · 40s
Immorta Bio finishes AI senolytic peptide trials
Immorta Bio completes preclinical studies for AI-designed senolytic peptide.
In brief
Immorta Bio completes preclinical studies for AI-designed senolytic peptide. Immorta Bio has completed preclinical studies for an AI-designed senolytic peptide to train immune cells to remove senescent cells. Originally reported by RuntimeWire.
Immorta Bio completes preclinical studies
Immorta Bio has completed planned preclinical studies for SenoMune-0257, an AI-designed nine-amino-acid peptide.
Peptide targets senescent cells
The peptide aims to train immune cells to remove senescent cells through immune-based senolytic therapy.
Next step: human testing
Immorta Bio plans human testing to test both the biology and its product strategy for immune-based senolytic therapy.
What it means
Immorta Bio has completed preclinical studies for an AI-designed senolytic peptide to train immune cells to remove senescent cells.
